Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.10 USD
12.67 M USD
233.66 M USD
140.42 M
About TG Therapeutics, Inc.
Sector
CEO
Michael Sean Weiss
Headquarters
Morrisville
Website
Founded
1993
FIGI
BBG000FVZQY1
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
TG Therapeutics (TGTX) Analysis Company Overview: TG Therapeutics NASDAQ:TGTX is a biopharmaceutical company focused on developing and commercializing innovative treatments for B-cell diseases. The company's recent FDA approval of BRIUMVI for relapsing multiple sclerosis (RMS) marks a significant milestone, positioning TG Therap
New Setup: TGTXTGTX: I have a green setup signal(dot Indictor). It has an excellent risk-to-reward ratio(RR:). I'm looking to enter long near the close of the day if the stock can manage to CLOSE above the last candle highs(white line). If triggered, I will then place a stop-loss below(SL) and a price target above
Short potential on TGTXShort-term structural looks bullish for TGTX.
But looking on bigger perspective TGTX is having structural bearishnes for years.
Possible short setup at 30ish level.
TGTX, 3/1-3/8, -2% lossOn 2/28/2024, TG Therapeutics (TGTX) reported a loss of $0.09 per share on revenue of $43.97 million for the fourth quarter ended December 2023. The consensus estimate was a loss of $0.12 per share on revenue of $40.06 million.
TGTX Its a point where it can go buy from, but its a weak price point at $17 - $18. it has to show me a reversal pattern to consider buying from those prices.
The best situation is if the price decreases to around $13 - $14 to buy until $25 that's 80% growth.
TG Therapeutics Gains After Strong Q3 BeatTG Therapeutics (NASDAQ:TGTX) added ~21% pre-market Wednesday after the company posted solid topline and bottom-line beats with its Q3 2023 financials.
The Morrisville, North Carolina-based biotech reported $165.8M in net revenue for the quarter, up from $94M in the prior-year period, exceeding the
$TGTX 4R trade ideaTGTX on pullback to the OB can benefit with a 4R is my thought. let me know what you think
$TGTX LongFalling wedge within a larger broadening wedge.
Daily hidden bullish divergence.
Strong bull trend above the 150MA.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of TGTX is 31.15 USD — it has increased by 2.74% in the past 24 hours. Watch TG Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange TG Therapeutics, Inc. stocks are traded under the ticker TGTX.
TGTX stock has risen by 1.80% compared to the previous week, the month change is a 35.08% rise, over the last year TG Therapeutics, Inc. has showed a 146.83% increase.
We've gathered analysts' opinions on TG Therapeutics, Inc. future price: according to them, TGTX price has a max estimate of 55.00 USD and a min estimate of 9.00 USD. Watch TGTX chart and read a more detailed TG Therapeutics, Inc. stock forecast: see what analysts think of TG Therapeutics, Inc. and suggest that you do with its stocks.
TGTX reached its all-time high on Mar 14, 2000 with the price of 149,411.41 USD, and its all-time low was 0.96 USD and was reached on Dec 29, 2011. View more price dynamics on TGTX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
TGTX stock is 6.99% volatile and has beta coefficient of 1.19. Track TG Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is TG Therapeutics, Inc. there?
Today TG Therapeutics, Inc. has the market capitalization of 4.72 B, it has decreased by −13.12% over the last week.
Yes, you can track TG Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
TG Therapeutics, Inc. is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
TGTX earnings for the last quarter are 0.02 USD per share, whereas the estimation was 0.03 USD resulting in a −33.33% surprise. The estimated earnings for the next quarter are 0.09 USD per share. See more details about TG Therapeutics, Inc. earnings.
TG Therapeutics, Inc. revenue for the last quarter amounts to 83.88 M USD, despite the estimated figure of 81.70 M USD. In the next quarter, revenue is expected to reach 98.80 M USD.
TGTX net income for the last quarter is 3.88 M USD, while the quarter before that showed 6.88 M USD of net income which accounts for −43.60% change. Track more TG Therapeutics, Inc. financial stats to get the full picture.
No, TGTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 264.00 employees. See our rating of the largest employees — is TG Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TG Therapeutics, Inc. EBITDA is −196.00 K USD, and current EBITDA margin is 9.01%. See more stats in TG Therapeutics, Inc. financial statements.
Like other stocks, TGTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TG Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TG Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TG Therapeutics, Inc. stock shows the buy signal. See more of TG Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.